Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Nonmetastatic Tumors Release Proteins That Condition the Body Against Cancer Spread

By BiotechDaily International staff writers
Posted on 04 Jun 2013
Image: Contributing author Dr. Randolph Watnick (Photo courtesy of Harvard Medical School).
Image: Contributing author Dr. Randolph Watnick (Photo courtesy of Harvard Medical School).
Cancer researchers have found that certain cancers that do not metastasize, produce and secrete the protein thrombospondin-1 (Tsp-1) and, by doing so, condition distant organs to suppress metastasis.

Tsp-1 is a member of the thrombospondin family of multidomain matrix glycoproteins and has been shown to be a natural inhibitor of neovascularization and tumorigenesis in healthy tissue. Tsp-1 interacts with at least 12 cell adhesion receptors, including CD36, alpha-v and beta-1 integrins, syndecan, and integrin-associated protein (IAP or CD47). It also interacts with numerous proteases involved in angiogenesis, including plasminogen, urokinase, matrix metalloproteinase, thrombin, cathepsin, and elastase.

Investigators at the Harvard Medical School (Boston, MA, USA) had previously shown that tumors that did not metastasize released the protein prosaposin. This protein in turn activated the potent antiangiogenic expression of Tsp-1. Prosaposin is a precursor for four cleavage products: saposins A, B, C, and D. Saposin is an acronym for Sphingolipid Activator PrO[S]teINs. Each domain of the precursor protein is approximately 80 amino acid residues long with nearly identical placement of cysteine residues and glycosylation sites. Saposins localize primarily to the lysosomal compartment of cells where they facilitate the catabolism of glycosphingolipids with short oligosaccharide groups.

In the current study, the investigators performed bone marrow transplant and gene knockout experiments on mouse models of metastatic and nonmetastatic prostate, breast, and lung tumors.

They reported in the May 2013 issue of the journal Cancer Discovery that both types of tumor induced cells from bone marrow monocytes expressing the Gr1 surface marker to migrate to the lungs. However, nonmetastatic tumors produced and secreted the protein prosaposin, which induced production of Tsp-1 by these monocytes. A review of the clinical literature revealed that prostate cancer patients whose tumors expressed higher levels of prosaposin had significantly greater overall survival than patients whose tumors expressed low levels of prosaposin.

Genetic deletion of Tsp-1 from the bone marrow abolished the inhibition of metastasis, which could then be restored by bone marrow transplant from Tsp-1-positive donors.

"In the past, we have struggled to determine the source of thrombospondin-1 production," said contributing author Dr. Randolph Watnick, assistant professor of surgery at Harvard Medical School. "We knew it was coming from the tumor microenvironment, normal cells adjacent to the sites of potential metastasis, but we could not tell if those cells were native to the microenvironment or had been recruited from the bone marrow. Others have shown that tumors recruit monocytes to future metastatic sites, which help to set up a permissive environment for tumor cells to metastasize. Our results suggest that nonmetastatic tumors do the same thing, but instead of creating a permissive environment, the monocytes create a refractory environment by producing thrombospondin-1."

The investigators described the development of a five-amino acid peptide from prosaposin that was able to induce Tsp-1 expression in Gr1-positive bone marrow cells, which dramatically suppressed metastasis.

"The size of this peptide makes it ideal for drug development," said Dr. Watnick. "It is about as large as tyrosine kinase inhibitors such as Gleevec or Iressa, and could potentially be formulated in multiple ways for different types of cancer. I could also foresee using a therapeutic agent like this peptide as an adjuvant therapy, for example just as we now use chemotherapy or hormonal therapy for breast cancer."

Related Links:

Harvard Medical School



BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.